RxDoctor Payments Data

Sameer Naik, MD

Family Practice · Pontiac, MINPI 1952587453

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 79.9% of it on its own, with 3 other manufacturers making up the rest. Among family practice clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$398in general payments, 2019–2025

Across 32 payments — averaging $12.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$318
  • Kowa Pharmaceuticals America, Inc.$55
  • AbbVie$14
  • Regeneron Healthcare Solutions, Inc.$11

What the payments were for

  • Food & beverage$398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$398 in reported general payments places this provider in the 95th percentile of 618 family practice providers in Michigan.

See all family practice providers in Michigan

Medicare billing

Part B allowed, 2024
$543,166
Medicare patients
493
Services billed
18,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate92$91,583
JardianceEmpagliflozin57$64,875
EliquisApixaban61$59,766
OzempicSemaglutide25$46,857
XareltoRivaroxaban31$37,556
LivaloPitavastatin Calcium50$33,809
ProliaDenosumab17$28,647
MounjaroTirzepatide16$17,201
TradjentaLinagliptin17$16,604
Rosuvastatin Calcium681$9,985
Pitavastatin Calcium19$8,874
Atorvastatin Calcium661$7,739
Olmesartan Medoxomil195$5,939
Valsartan165$5,622
Ezetimibe228$5,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kowa Pharmaceuticals America, Inc.Livalo$55$33,80950 claims
AmgenProlia$318$28,64717 claims
AbbVieSynthroid$14$4,94994 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 family practice providers in Michigan.

Other family practice in Pontiac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →